Αποτελέσματα Αναζήτησης
Milrinone is a partial competitive inhibitor of phosphodiesterase III (PDE-III), with a measured IC 50 value of between 0.66 and 1.3 μM. 3,7 As a PDE-III inhibitor, milrinone results in an increase in intracellular cAMP, responsible for its pharmacological effects, including positive inotropy, positive lusitropy, and vasodilation. 1,2,4 As ...
- CRS
Back to Milrinone. Indications Status Purpose Phase;...
- Milrinone Completed Phase 2 Trials for Milrinone / Vascular Spasm After Traumatic Subarachnoidhaemorrhage / Oral Nimodipine Treatment
DBCOND0144157 (Milrinone) DBCOND0144158 (Vascular Spasm...
- CRS
28 Αυγ 2020 · Milrinone is a medication indicated for cardiac support in patients with acute heart failure, pulmonary hypertension, or chronic heart failure. It improves cardiac contractility (inotropy) and cardiac relaxation (lusitropy) and induces vasodilation.
Η μιλρινόνη (milrinone) είναι ένας εκλεκτικός αναστολέας της φωσφοδιεστεράσης και αυξάνει την ενδοκυττάρια συγκέντρωση του cAMP, με αποτέλεσμα την αύξηση του ενδοκυτταρίου ασβεστίου και συνεπώς της συσταλτικότητας.
Milrinone, sold under the brand name Primacor, is a pulmonary vasodilator [2] used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance.
Milrinone is a nonglycoside, nonbeta-adrenergic positive inotropic agent that was introduced recently for the treatment of CHF.
18 Ιουν 2020 · The Mil HFPEF (Extended Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction) study was a randomized, double‐blind, placebo‐controlled pilot study in 23 patients with symptomatic HF p EF.
Includes Milrinone indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse reactions, off-label uses and more.
